TCF3: HLf-Positive B-ALL Integrated Clinical and Molecular Characterization

04 Apr 20264 min read0 viewsJournal Feed

GIST

British Journal of Cancer, Published online: 04 April 2026; doi:10.1038/s41416-026-03370-9 TCF3 :: HLF -positive B-ALL: integrated clinical and molecular characterization of 34 cases from a single-center cohort

Clinical Editorial

Summary

British Journal of Cancer published a clinical update in Oncology on 04 Apr 2026.

The item focuses on TCF3 :: HLF -positive B-ALL: integrated clinical and molecular characterization of 34 cases from a single-center cohort.

Review the original article for the full source wording and details.

Source Reference

Read the full original publication from the source journal or publisher link below.

Open Original Source More Feed Items

Related by Condition/Drug

Nat Rev OncRelated by Specialty

Current evidence and future directions for KIM-1 as a blood-based biomarker in RCC

Oncology • 20 May 2026

Br J CancerRelated by Specialty

Differential effects of prior versus concomitant Steroid and Antibiotic Treatment on Immunotherapy Efficacy - A Pooled Analysis of the RAMONA, INTEGA, OPTIM, ELDORANDO, FORCE, TITAN-RCC and TITAN-TCC Trials of the German AIO Study Group

Oncology • 19 May 2026

Nat Rev OncRelated by Specialty

Transforming perioperative treatment of gastro-oesophageal adenocarcinoma: triumphs, setbacks and future horizons

Oncology • 15 May 2026

JAMA OncRelated by Specialty

Generalizability and Fairness in Deploying AI for Lung Cancer Biomarker Prediction

Oncology • 14 May 2026

NatureRelated by Specialty

Autonomous pathology research using agentic AI shows potential in oncology

Oncology • 05 May 2026

Br J CancerRelated by Specialty

SLIRP Maintains Mitochondrial mRNA Stability and OXPHOS in Colorectal Cancer

Oncology • 28 Apr 2026

Feed Metadata

Source

British Journal of Cancer